<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628381</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-08</org_study_id>
    <secondary_id>ZON/NW 40-00806-98-114</secondary_id>
    <nct_id>NCT00628381</nct_id>
  </id_info>
  <brief_title>L-citrulline Supplementation During Sepsis</brief_title>
  <official_title>Arginine and Nitric Oxide (NO) Metabolism in Sepsis; L-citrulline Enteral Supplementation for the Normalisation of the Arginine-NO Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the stimulating effects of prolonged (8h) enteral
      L-citrulline supplementation on the normalisation of the plasma citrulline concentrations and
      the Arginine-NO metabolism, the microcirculation, the systemic hemodynamics, vascular
      permeability, and organ function and disease severity scores.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NO synthesis is compromised during sepsis through lack of arginine de novo synthesis and may
      thereby contribute to impaired microcirculation and organ dysfunction. Supplementation of
      L-citrulline in septic patients will increase NO production without increased arginase
      activity and these effects will be studied on arginine-NO metabolism,improved organ function,
      vascular permeability and microcirculation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study stimulating effects of prolonged (8h) enteral L-citrulline supplementation on the normalisation of the arginine-NO metabolism</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary study endpoints are the microcirculation, the vascular permeability and organ function scores.</measure>
    <time_frame>within 8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Sepsis</condition>
  <condition>Multiple Organ Failure</condition>
  <arm_group>
    <arm_group_label>AA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 ICU patients with severe sepsis will get a L-citrulline 8 h enteral supplementation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 ICU patients with severe sepsis will get an alternative isocaloric amino acid supplementation (L-alanine) during 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-citrulline supplementation</intervention_name>
    <description>L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented</description>
    <arm_group_label>AA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-alanine</intervention_name>
    <description>L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented</description>
    <arm_group_label>AB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from close relative

          -  Age &gt; 18 years

          -  Patient meets the general criteria for severe sepsis or septic shock, diagnosed less
             than 48 h prior to study inclusion.

          -  Patient must be relatively hemodynamically stable, defined as stable blood pressure
             (variation in mean arterial pressure &lt;15 mm Hg) during 2h without necessity of
             increasing the vasopressor dose, inotropic support or rate of fluid administration.

          -  Systemic arterial catheter in place with continuous pressure monitoring.

          -  Patients in whom the clinician is prepared to provide full life support during the
             duration of the study

        Exclusion Criteria:

          -  Shock due to any cause other than sepsis (e.g. drug reaction or drug overdose,
             pulmonary embolus, burn injury etc.)

          -  Prolonged or high dose corticosteroid use

          -  Liver cirrhosis

          -  Chronic pancreatitis

          -  Insulin-dependent diabetes mellitus

          -  Metastases, haematological malignancies or chemotherapy

          -  Patients on dialysis (CVVH or other)

          -  Pre-existent renal failure (on dialysis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martijn Poeze, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Wijnands, MD, PhD-student</last_name>
    <phone>+31-43-3884502</phone>
    <email>n.wijnands@ah.unimaas.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martijn Poeze, MD, PhD</last_name>
    <phone>+31-43-3874425</phone>
    <email>m.poeze@ah.unimaas.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martijn Poeze, MD, PhD</last_name>
      <phone>+31-43 3876543</phone>
      <email>m.poeze@ah.unimaas.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nina Wijnands, MD, PhD-student</last_name>
      <phone>+31-43-3884502</phone>
      <email>n.wijnands@ah.unimaas.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Rougé C, Des Robert C, Robins A, Le Bacquer O, Volteau C, De La Cochetière MF, Darmaun D. Manipulation of citrulline availability in humans. Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1061-7. Epub 2007 Sep 27.</citation>
    <PMID>17901164</PMID>
  </reference>
  <reference>
    <citation>Barr FE, Tirona RG, Taylor MB, Rice G, Arnold J, Cunningham G, Smith HA, Campbell A, Canter JA, Christian KG, Drinkwater DC, Scholl F, Kavanaugh-McHugh A, Summar ML. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg. 2007 Aug;134(2):319-26.</citation>
    <PMID>17662768</PMID>
  </reference>
  <reference>
    <citation>Lehr HA, Bittinger F, Kirkpatrick CJ. Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy? J Pathol. 2000 Feb;190(3):373-86. Review.</citation>
    <PMID>10685071</PMID>
  </reference>
  <reference>
    <citation>Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998 Nov 15;336 ( Pt 1):1-17. Review.</citation>
    <PMID>9806879</PMID>
  </reference>
  <reference>
    <citation>Hallemeesch MM, Lamers WH, Deutz NE. Reduced arginine availability and nitric oxide production. Clin Nutr. 2002 Aug;21(4):273-9. Review.</citation>
    <PMID>12135586</PMID>
  </reference>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <last_update_submitted>September 2, 2010</last_update_submitted>
  <last_update_submitted_qc>September 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>M.Poeze, MD, PhD,</name_title>
    <organization>Department of surgery, University hospital Maastricht</organization>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>microcirculation</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>citrulline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

